Thomas McCarty
Gastroenterology · Houston, TXNPI 1376955047
Payments from drug & device makers
Across 177 payments — averaging $194.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$27K
- Medtronic$2K
- Fujifilm Healthcare Americas Corporation$893
- Olympus Corporation Of The Americas$699
- AbbVie$542
- Apollo Endosurgery US Inc$438
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$2,2006%
- Grants$25,00073%
- Travel & lodging$1,2724%
- Food & beverage$5,93217%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $26,573 |
| Medtronic | 7 | $2,477 |
| Fujifilm Healthcare Americas Corporation | 10 | $893 |
| Olympus Corporation Of The Americas | 6 | $699 |
| AbbVie | 38 | $542 |
| Apollo Endosurgery US Inc | 6 | $438 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $404 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $260 |
| Johnson & Johnson | 6 | $251 |
| Celltrion USA Inc. | 7 | $236 |
| Olympus America Inc. | 2 | $188 |
| Cook Medical LLC | 2 | $182 |
| Creo Medical Inc. | 2 | $178 |
| Sanofi | 5 | $134 |
| Regeneron Healthcare Solutions, Inc. | 5 | $119 |
| Steris Corporation | 1 | $92 |
| Novo Nordisk | 1 | $85 |
| Lilly USA, LLC | 3 | $79 |
| Aimmune Therapeutics, Inc. | 4 | $77 |
| Ovesco Endoscopy USA, Inc. | 1 | $75 |
| 3-d Matrix, Inc. | 1 | $73 |
| Phathom Pharmaceuticals, Inc. | 4 | $71 |
| Merck | 4 | $65 |
| Lumendi LLC | 1 | $43 |
| Pharmacosmos Therapeutics Inc. | 2 | $39 |
| Braintree Laboratories, Inc. | 2 | $34 |
| Ambu Inc. | 1 | $27 |
| Sandoz | 1 | $25 |
| Alcresta Therapeutics, Inc. | 1 | $24 |
| CSL Behring | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - BILIARY DEVICES$25,000
- SPYGLASS$1,017
- VISIGLIDE$594
- Single Use Electrosurgical Knife KD-655$594
- DISPOSABLE DISTAL ATTACHMENT$594
- Olympus$594
- X-Tack Endoscopic HeliX Tacking System$503
- FUJIFILM$442
- ORBERA Intragastric Balloon System$425
- Single Use Aspiration Needle NA-U200H$334
- OverStitch Endoscopic Suturing System$251
- Beacon$149
- GENERAL - THERAPIES$143
- Hemospray$127
- Tremfya$127
- VEGZELMA$120
- SPEEDBOAT$116
- EndoClot PHS$101
How this compares
$34,404 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 21 | $31,090 |
| LinzessLinaclotide | 30 | $15,816 |
| MounjaroTirzepatide | 12 | $12,620 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 59 | $3,561 |
| Lubiprostone | 20 | $3,120 |
| Pantoprazole Sodium | 207 | $2,158 |
| Sucralfate | 39 | $1,031 |
| Omeprazole | 52 | $878 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 55 | $845 |
| Dicyclomine Hcl | 13 | $442 |
| Famotidine | 53 | $392 |
| Esomeprazole Magnesium | 14 | $382 |
| Hydrocortisone | 17 | $278 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 21 | $261 |
| Clarithromycin | 11 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $542 | $46,90751 claims |
| Lilly USA, LLCMounjaro | $79 | $12,62012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Mazen NoureddinHouston$6.1M
- James MaherHouston$5.3M
- Uma MohanHouston$5M
- John VierlingHouston$2.8M
- Bincy AbrahamHouston$2.5M
- Jason HouHouston$2.3M
- Jignesh ShahHouston$1.7M
- Mouhamad Al-SabbaghHouston$1.6M
- Mohamed OthmanHouston$1.6M
- Harry OjeasHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.